Viriom

Viriom is a late-stage biotech company

Viriom Inc. is a late stage biotech company developing novel and affordable therapies against life threatening infections such as HIV and HBV. The company has an exclusive worldwide license to its phase 2/3 stage lead compound (Elpida/VM-1500) from Hoffmann-La Roche for HIV and has developed proprietary pre-clinical lead compound VM-1010 as potentially curative treatment of chronic HBV. Viriom believes its drug candidates are capable of making a breakthrough in treating and preventing HIV and chronic HBV infections in both developing and developed countries.